Evinacumab in Patients with Refractory Hypercholesterolemia.

The New England Journal of Medicine
Robert S RosensonDaniel Gaudet

Abstract

Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known. In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hypercholesterolemia who had refractory hypercholesterolemia, with a screening LDL cholesterol level of 70 mg per deciliter or higher with atherosclerosis or of 100 mg per deciliter or higher without atherosclerosis. Patients were randomly assigned to receive subcutaneous or intravenous evinacumab or placebo. The primary end point was the percent change from baseline in the LDL cholesterol level at week 16 with evinacumab as compared with placebo. In total, 272 patients were randomly assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 patients), or 300 mg every 2 weeks (39 patients) or placebo (41 patients); or intravenous evinacumab at a dose of 15 mg per kilogra...Continue Reading

References

Oct 15, 2010·The New England Journal of Medicine·Kiran MusunuruSekar Kathiresan
Feb 19, 2015·Current Opinion in Endocrinology, Diabetes, and Obesity·Hagai TavoriSergio Fazio
May 13, 2015·Journal of Lipid Research·Viktoria GusarovaJesper Gromada
Oct 30, 2015·Circulation·Samuel S GiddingUNKNOWN American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascula
Jan 13, 2016·Endocrine·Anna Tikka, Matti Jauhiainen
Apr 7, 2016·Journal of the American College of Cardiology·Amit V KheraSekar Kathiresan
Jul 8, 2016·Journal of the American Heart Association·Anthony WangPeter P Toth
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
May 18, 2017·The New England Journal of Medicine·A Michael LincoffUNKNOWN ACCELERATE Investigators
May 26, 2017·The New England Journal of Medicine·Frederick E DeweyAris Baras
Jul 21, 2017·The New England Journal of Medicine·Daniel GaudetG Kees Hovingh
Sep 2, 2017·Journal of the American College of Cardiology·Robert S RosensonPaul D Thompson
Oct 7, 2017·Nature Reviews. Endocrinology·Sander Kersten
Jul 26, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Beate BittnerJohannes Schmidt
Oct 3, 2018·Atherosclerosis·Frederick J RaalAlberico L Catapano
Dec 18, 2018·Journal of Atherosclerosis and Thrombosis·Yasushi IshigakiShinichi Oikawa
Jan 30, 2019·JAMA : the Journal of the American Medical Association·Brian A FerenceAlberico L Catapano
Feb 1, 2019·Circulation Research·Robert S RosensonWolfgang Koenig
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Dec 17, 2019·Journal of the American Heart Association·Mary P McGowanP Barton Duell
Feb 15, 2020·Journal of the American College of Cardiology·Raul D SantosFrederick J Raal
May 23, 2020·Journal of the American College of Cardiology·Sabina O BeheshtiBørge G Nordestgaard
Jul 21, 2020·Atherosclerosis·Antonio GalloUNKNOWN French REgistry of Familial hypERCHOLesterolemia (REFERCHOL) investigators
Aug 20, 2020·The New England Journal of Medicine·Frederick J RaalUNKNOWN ELIPSE HoFH Investigators

❮ Previous
Next ❯

Citations

Nov 26, 2020·Nature Reviews. Cardiology·Gregory B Lim
Dec 10, 2020·The New England Journal of Medicine·Seth S Martin
Feb 11, 2021·The New England Journal of Medicine·Mehmet Agirbasli
Feb 11, 2021·The New England Journal of Medicine·Hua-Guo Xu
Feb 19, 2021·Future Cardiology·Rama HritaniAnandita Agarwala
Mar 7, 2021·Journal of Lipid Research·Kévin ChemelloDirk Blom
Feb 11, 2021·The New England Journal of Medicine·Frederick J RaalViktoria Gusarova
Mar 12, 2021·Current Atherosclerosis Reports·Massimiliano RuscicaAlberto Corsini
Mar 13, 2021·Cardiovascular Drugs and Therapy·Aleesha Shaik, Robert S Rosenson
Mar 16, 2021·Journal of Lipid Research·Robert S Rosenson
Feb 11, 2021·The New England Journal of Medicine·Fei LuoZhenfei Fang
Apr 6, 2021·Current Opinion in Cardiology·Praneet K GillRobert A Hegele
Apr 13, 2021·Advances in Therapy·Aileen KearneyIan B A Menown
Apr 11, 2021·Journal of Cardiovascular Pharmacology and Therapeutics·Semira Abdi BeshirAmira S A Said
Apr 24, 2021·Circulation. Genomic and Precision Medicine·Nicholas B BlackburnJoanne E Curran
Apr 27, 2021·Current Opinion in Lipidology·Qidi YingGerald F Watts
May 11, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Leopoldo Pérez de Isla, Pedro Valdivielso
May 19, 2021·Drugs·Anthony Markham
May 1, 2021·Current Opinion in Cardiology·Camelia C DiaconuManfredi Rizzo
May 30, 2021·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Giorgio A MedrandaRon Waksman
Jun 11, 2021·Circulation Research·Marc P BonacaMark A Creager
May 29, 2021·Diabetes, Obesity & Metabolism·Ping LingJianping Weng
Jun 20, 2021·Current Atherosclerosis Reports·Marcio H MinameRaul D Santos
Jul 31, 2021·American Journal of Preventive Cardiology·David I FeldmanGarima Sharma
Jul 14, 2021·Expert Review of Cardiovascular Therapy·Bruce A Warden, P Barton Duell
Aug 3, 2021·American Journal of Physiology. Endocrinology and Metabolism·Kelli L Sylvers-Davie, Brandon S J Davies
Jun 13, 2021·Journal of Cardiovascular Pharmacology·Menglong JinZhenyan Fu
Oct 27, 2021·Current Atherosclerosis Reports·Angela PirilloGiuseppe D Norata
Sep 29, 2021·Current Opinion in Lipidology·Sander Kersten

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.